FDA Approves IBANDRONATE SODIUM — Apotex Corp.

# FDA Approves Apotex's Generic Ibandronate Sodium Injection Apotex Corp. received FDA approval for its generic ibandronate sodium intravenous formulation, expanding the competitive landscape in the osteoporosis treatment market and potentially reducing patient costs for this quarterly injection therapy. The approval of the generic alternative to the branded version is expected to increase price competition and improve market access for the intravenous bisphosphonate treatment.